Guides for diagnostic development

RUO vs GLP vs LDT vs IVD: which do you need?

The label depends on what results will be used for and who runs the test. RUO is for research, never patient care. GLP is for nonclinical safety studies that support an FDA application. An LDT lets one CLIA-certified lab report patient results. An IVD is FDA-cleared or approved and can be sold to, or run by, other labs or consumers.

At a glance

The four labels compared

Research

RUO

Results used for

Research only; no patient management

Who runs it

Any lab, for research

Oversight

None for the use; FDA polices RUO labeling

Typical use

Discovery, biomarker work, assay development

Nonclinical

GLP

Results used for

Nonclinical safety studies submitted to FDA

Who runs it

A GLP testing facility with a study director and independent QA unit

Oversight

FDA GLP regulations (21 CFR Part 58) and FDA inspection

Typical use

Bioanalysis and biomarkers in toxicology studies for an IND

Clinical

LDT

Results used for

Patient care, reported by the lab that developed it

Who runs it

One CLIA-certified lab

Oversight

CLIA (CMS), CAP accreditation, state rules such as New York's

Typical use

Specialty testing, early clinical launch

Product

IVD

Results used for

Patient care, wherever the cleared test is run

Who runs it

Any lab certified for its CLIA complexity; only the named lab if site-specific; consumers if cleared for home use

Oversight

FDA (510(k), De Novo or PMA), plus CLIA for the lab

Typical use

Kits, home tests, companion diagnostics

RUO: for research, not patients

RUO is the right label for discovery work: finding biomarkers, building and optimizing an assay, or running exploratory samples. An RUO product carries no clinical claims and FDA does not review it. The common mistake is using RUO results to guide a patient's care: FDA treats RUO-labeled products marketed for clinical use as misbranded. Careful optimization and early precision work at this stage can carry forward into later validation.

GLP: nonclinical studies for FDA

GLP applies when an assay produces data for a nonclinical laboratory study, such as drug levels or biomarkers in a toxicology study supporting an IND. The rules are in 21 CFR Part 58. GLP governs how the study is run, not the test's label: a written protocol and single study director, an independent quality assurance unit, a method validated before study samples are run, SOPs and archived raw data, and readiness for FDA inspection. It does not cover human samples from clinical trials (GCLP) or patient testing (CLIA).

LDT: patient results from one lab

An LDT is designed, validated and run within a single CLIA-certified laboratory, the fastest route to reporting patient results. CLIA, administered by CMS, certifies the lab and inspects its validation; many labs also hold CAP accreditation, and New York's Clinical Laboratory Evaluation Program reviews tests offered to New York patients. FDA's 2024 rule to regulate most LDTs as devices was vacated by a federal court on March 31, 2025; FDA did not appeal and has rescinded the rule. Legislation and CMS action on CLIA were pending as of mid-2026, so build validations that would stand up to FDA-level review anyway.

IVD: an FDA-reviewed product

You need IVD authorization to sell a kit to other labs, offer a test direct to consumers, or support a drug label as a companion diagnostic. Moderate-risk tests with a predicate use a 510(k); new moderate-risk tests use De Novo; high-risk tests, including most companion diagnostics, need a PMA. A clearance can be site-specific, covering the test as run in one named laboratory, as in our GlutenID case study.

How to choose

Answer these in order

  1. Research only, with no effect on patient care or a regulatory filing? RUO.
  2. Data from a nonclinical safety study submitted to FDA? GLP.
  3. Results used in a clinical trial? Validate under GCLP; if results guide treatment, FDA may require an investigational device exemption.
  4. Will a drug's label depend on the test? IVD, usually a PMA companion diagnostic.
  5. Selling a kit to other labs or testing consumers directly? IVD.
  6. One lab running the test and reporting to clinicians? LDT under CLIA, with New York approval for New York patients.
Many programs pass through several stages. Design each study for the stage after it: data collected to the next standard saves repeating work.

Sources: FDA RUO/IUO guidance · 21 CFR Part 58 · FDA Law Blog, April 2025 · Arnold & Porter, July 2026

Not sure which label your test needs?

We develop and validate assays at every level, run LDTs in our CLIA/CAP laboratory, and prepare FDA submissions.